News Release

Common genetic variants associated with development of high-risk neuroblastoma

Poorer treatment outcomes

Peer-Reviewed Publication

American Association for Cancer Research

WASHINGTON, D.C. — Patients with a high degree of African ancestry had a greater incidence of high-risk neuroblastoma and poorer outcomes, according to preliminary results presented here at the Fourth AACR Conference on The Science of Cancer Health Disparities, held here Sept. 18-21, 2011.

"There are common genetic variants that are associated with the development of high-risk neuroblastoma and a poor outcome," said Navin R. Pinto, M.D., instructor of pediatrics at the University of Chicago in Chicago, Ill. "These variants are more common in patients of African origin, but have the potential to be present and affect patients of all ethnic backgrounds. Identifying patients with these variants at the time of diagnosis may one day allow us to modify treatment for those who are genetically at risk for treatment failure with standard therapies."

Neuroblastoma is a childhood cancer with a widely variable clinical outcome, Pinto said. Some children do well with no therapy, while others die despite aggressive chemotherapy, surgery, stem cell transplant and immunotherapy.

In a previous study of 3,539 children with neuroblastoma, Pinto and colleagues found that patients who self-reported as black were much more likely to have high-risk disease and have an increased incidence of late relapses, suggesting that germline genetic differences linked with ethnicity or ancestry may influence disease development.

For this follow-up study of 3,508 racially mixed children with neuroblastoma, the researchers obtained germline genotypes from investigators at the Children's Hospital of Philadelphia. They then created an ancestral map using the patients' genotypes and the publicly available genotypes of three ancestral populations: African, Asian and white.

Children with a higher degree of African ancestry had increased rates of high-risk disease and lower survival rates following chemotherapy, according to the study's preliminary findings.

"This indicates that African ancestors may have passed along common genetic variants that are associated with the development of the aggressive form of neuroblastoma and perhaps a relative intrinsic chemotherapy resistance that is associated with the observed inferior outcomes," Pinto said.

Armed with these findings, researchers can now focus on the specific genetic variants linked with inferior outcome, Pinto said. These variants may be found in patients of any ethnic makeup, not just African ancestry.

"The remarkable improvements in cure rates for childhood malignancies over the past 50 years have, in large part, come from recognizing clinical or biological features that are associated with a poor outcome and intensifying therapy for patients at high risk of non-response," Pinto said. "Germline genetic variables will likely one day be included in risk stratification algorithms for the treatment of neuroblastoma. I believe we are on the cusp of discovering these variants."


Follow the AACR on Twitter: @aacr #aacr

Follow the AACR on Facebook:

The mission of the American Association for Cancer Research is to prevent and cure cancer. Founded in 1907, the AACR is the world's oldest and largest professional organization dedicated to advancing cancer research. The membership includes 33,000 basic, translational and clinical researchers; health care professionals; and cancer survivors and advocates in the United States and more than 90 other countries. The AACR marshals the full spectrum of expertise from the cancer community to accelerate progress in the prevention, diagnosis and treatment of cancer through high-quality scientific and educational programs. It funds innovative, meritorious research grants, research fellowships and career development awards. The AACR Annual Meeting attracts more than 18,000 participants who share the latest discoveries and developments in the field. Special conferences throughout the year present novel data across a wide variety of topics in cancer research, treatment and patient care. The AACR publishes seven major peer-reviewed journals: Cancer Discovery; Cancer Research; Clinical Cancer Research; Cancer Epidemiology, Biomarkers & Prevention; Molecular Cancer Therapeutics; Molecular Cancer Research; and Cancer Prevention Research. AACR journals received 20 percent of the total number of citations given to oncology journals in 2010.

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.